Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.

Oncogene - 1 Aug 2018

Yoon Sarah, Lee Eun-Ju, Choi Ji-Hye, Chung Taek, Kim Do Young, Im Jong-Yeop, Bae Myung-Ho, Kwon Jung-Hee, Kim Hyuk-Hoon, Kim Hyung Chul, Park Young Nyun, Wang Hee-Jung, Woo Hyun Goo

Abstract excerpt

Gene mutations play critical roles during cancer development and progression, and therefore represent targets for precision medicine. Here we recapitulated the pharmacogenomic data to delineate novel candidates for actionable mutations and therapeutic target drugs. As a proof-of-concept, we demonstrated that the loss-of-function of SULF2 by mutation (N491K) or inhibition enhanced sorafenib sensitivity in liver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipocalin-2

Share to Liver Neoplasms

Share to Pharmacogenetics

Share to Sorafenib

Share to Sulfatases

Share to Sulfotransferases

Source

Identifiers

PMID: 29720727
DOI: 10.1038/s41388-018-0291-3

Genes

SULF2
LCN2
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.PMID 29720727Read ↗

ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular CarcinomaSemantic proximity Read ↗

Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2–Platelet‐Derived Growth Factor Receptor Beta–Yes‐Associated Protein Signaling AxisSemantic proximity Read ↗

SENP1 is a crucial promotor for hepatocellular carcinoma through deSUMOylation of UBE2T.Semantic proximity Read ↗

Validation of a multi-omics strategy for prioritizing personalized candidate driver genesSemantic proximity Read ↗

SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.Semantic proximity Read ↗

Serglycin-Mediated Selective Reactivation of the Novel YAP/CRISPLD2 Developmental Axis Promotes Metastasis and Sorafenib Resistance in Hepatocellular CarcinomaSemantic proximity Read ↗

5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1/SLC7A11-mediated ferroptosisSemantic proximity Read ↗

Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applicationsSemantic proximity Read ↗

Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival.Semantic proximity Read ↗

Ring Finger Protein 141 (RNF141) Mediates Resistance to Sorafenib in Hepatocellular Carcinoma and Its MechanismsSemantic proximity Read ↗

Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.Semantic proximity Read ↗

Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.